Page 262 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
male thalassemia major patients: pathophysiology, diagnosis
and treatment. Acta Bio-Medica Atenei Parm 2018;89(2-S):6-15.
12. Casale M, Forni GL, Cassinerio E, et al. Risk factors for
endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica. 2022;107(2):467-477.
13. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Am J Hematol. 2012;87(2):167-171.
14. Trachtenberg FL, Gerstenberger E, Xu Y, et al. Relationship
among chelator adherence, change in chelators, and quality of
life in thalassemia. Qual Life Res. 2014;23(8):2277-2288.
15. Albu A, Barbu CG, Antonie L, Vladareanu F, Fica S. Risk factors
associated with hypogonadism in b-thalassemia major patients: predictors for a frequent complication of a rare disease. Postgrad Med. 2014;126(5):121-127.
Haematologica | 109 July 2024
2276